Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.

ABSTRACT: Background Adjuvant tamoxifen therapy approximately halves the risk of estrogen receptor-positive (ER+) breast cancer recurrence, but many women do not respond to therapy. Observational studies nested in clinical trial populations suggest that overexpression or nuclear localization of p21-activated kinase 1 (Pak1) in primary tumors predicts tamoxifen failure. Material and methods We measured the association between Pak1 expression and breast cancer recurrence in a Danish population-based case-control study. Pak1 cytoplasmic expression level and nuclear positivity were determined by immunohistochemical staining of primary breast tumors from recurrence cases and matched controls from two breast cancer populations; women diagnosed with ER-positive tumors who received at least one year of tamo

SUBMITTER: Ahern TP 

PROVIDER: S-EPMC4943575 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature